Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Investing.com -- Ascendis Pharma A/S (NASDAQ:ASND) stock rose 1.8% in pre-market trading after the company announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA for the treatment of growth hormone deficiency (GHD) in adults.SKYTROFA (lonapegsomatropin-tcgd) is a once-weekly prodrug of somatropin that provides sustained release of active, unmodified human growth hormone. The FDA had previously approved the treatment for pediatric GHD in 2021, and this latest approval expands its use to the adult population.The approval was based on results from the Phase 3 foresiGHt clinical trial, which compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily somatropin in adults with GHD."Our market research shows SKYTROFA is the treatment of choice for pediatric GHD among patients and physicians, and we are pleased to expand its availability in the United States for the treatment of adults initiating therapy or switching from another growth hormone therapy," said Jan Mikkelsen, President and CEO at Ascendis Pharma.Dr. Kevin Yuen of Barrow Neurological Institute noted that adult GHD can lead to serious medical complications including metabolic syndrome, increased cardiovascular risk, and impaired quality of life. He highlighted that adherence to daily somatropin injections, which have been the standard of care for over 25 years, remains problematic for many patients.Ascendis Pharma described this approval as "the first of many planned label expansions" as the company aims to become a leading player in the endocrinology rare disease space.This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.